GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.

As India Suffers Crisis, Merck Signs License Pact with 5 Indian Firms to Manufacture COVID-19 Drugs

by Tyler Chen
Share To

India is currently facing a second wave of the COVID-19 outbreak. Since April 17th, its daily confirmed cases have exceeded over 250,000. The country is in great need of medical and monetary support to alleviate the pressure on the healthcare system.

Merck’s Pact with 5 Indian Manufacturers

Merck (MSD outside the United States and Canada) announced the non-exclusive voluntary licensing agreements for molnupiravir (EIDD-2801/MK-4482) with five Indian generics manufacturers.

Molnupiravir is an oral antiviral agent that is being studied in a Phase 3 trial for the non-hospitalized patients with confirmed COVID-19, and it is not approved in India at the moment.

Merck will grant licenses to Cipla, Dr. Reddy’s Laboratories, Emcure Pharmaceuticals, Hetero Labs, and Sun Pharmaceutical Industries Ltd. to manufacture molnupiravir for India and over 100 low- and middle-income countries. Furthermore, it will donate more than $5 million worth of oxygen-production equipment, masks, and financial aid to India.

Gilead Donates 450,000 Vials of Remdesivir

Besides Merck, Gilead has also stepped in to help India. The company said that it would provide technical assistance to India’s local manufacturers, expand local production capacity and donate active pharmaceutical ingredients (APIs) to scale up Veklury (remdesivir) production.

The antiviral drug has already been approved by India’s government for restricted emergency use. Gilead will donate at least 450,000 vials of remdesivir to meet the surging medical needs of the country.

Currently, India has approved three COVID-19 vaccines, Covaxin by Bharat Biotech, Russia Gamaleya’s Sputnik V, and AstraZeneca’s AZD1222. In India, AZD1222 is manufactured by the Serum Institute of India and sold under the name Covishield.

Related Article: New ‘Triple Mutant’ Deepens COVID-19 Crisis in India

 

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
MediBuddy Partners with Japan’s ELECOM to Launch Smart Health IoT Devices in India
2025-02-05
Pharma’s Growing (R)evolution: Sustainability and Innovations Shaping the Industry
2025-01-07
Biotech Giants Behind Partnerships in Precision Therapies, Gene Editing, and ADCs
2025-01-03
LATEST
Novo Nordisk Bets Big on CagriSema With A Heavyweight Move Planned for 2026
2025-02-07
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
First-of-its-Kind Diagnostic Aid Uses a Single Hair Strand to Detect Autism Risk in Babies
2025-02-06
Teladoc Dials Up Virtual Care with $70 Million Acquisition of Catapult
2025-02-06
Silicon Valley in the Crosshairs as EU Readies to Strike U.S. Big Tech
2025-02-06
Johnson & Johnson Under Fire Again as Legal Action Over Alleged Talc-Cancer Link Moves to the UK
2025-02-05
MediBuddy Partners with Japan’s ELECOM to Launch Smart Health IoT Devices in India
2025-02-05
EVENT
2025-02-05
Precision Medicine World Conference 2025
Santa Clara, California
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top